MMG Revises Remedies for Anglo American Nickel Bid

Hong Kong-listed MMG will submit a modified proposal to EU antitrust regulators for its $500 million Brazilian nickel acquisition.

Updated on Nov. 11, 2026 in Business Strategy

Wide view of a nickel processing plant on red-brown earth, with ore piles, a long conveyor belt, and industrial kilns under hazy late-afternoon light.
Hong Kong-listed MMG said on Tuesday it will submit revised remedies to European Commission antitrust regulators to win approval for its $500 million purchase of Anglo American's Brazilian nickel business. AI Illustration. Upload story photo >

MMG said it will revise its proposed remedies to the European Commission to secure EU antitrust approval for its $500 million bid for Anglo American's Brazilian nickel business. The company says the changes will increase ferronickel supplies to Europe and offer greater contract certainty and pricing flexibility.

Why it matters

The European Commission has warned that MMG could redirect ferronickel supplies away from Europe to China, making the remedies central to whether the deal clears review. The outcome will shape how the EU balances foreign investment in critical metals against regional supply security.

MMG's bid for Anglo American's Brazilian nickel business is valued at $500 million, while China's State-owned Minmetals holds 67% of MMG. The revised remedies have not yet been accepted by the European Commission, and their specific volume commitments remain unpublished.

The players

MMG

MMG is a Hong Kong-listed metals company, 67% owned by China's State-owned Minmetals, with other shareholders including BlackRock and Vanguard.

Anglo American

Anglo American is a global mining company that is selling its Brazilian nickel business to MMG.

European Commission

The European Commission is the EU's competition enforcer responsible for reviewing mergers and acquisitions for antitrust compliance.

The details

MMG said it will submit a modified remedies proposal to the European Commission following a closed hearing held earlier in November with Commission officials and third parties. MMG and Anglo American defended the deal at that hearing, and MMG says the revised proposal will resolve outstanding customer and regulator concerns.

Timeline

  1. Earlier in November 2026: Closed hearing held with European Commission officials and third parties.

  2. November 11, 2026: MMG announced it will revise its proposed remedies.

Market Landscape

The MMG review applies the EU Merger Regulation's remedies process to a bid by a China-linked acquirer for a critical metals asset. It sits within a wider pattern of Western regulators weighing supply security against foreign investment in strategic mineral supply chains.

The outcome of the remedies review will determine whether ferronickel supply to European customers is secured under contract. Customers relying on these supplies may see changes in contract terms and pricing if the deal proceeds.

The takeaway

Regulators increasingly weigh supply security alongside competition when reviewing deals in critical minerals. Companies pursuing such acquisitions should expect remedies that guarantee supply commitments to the regions most affected.

Further reading

For broader context on how companies position major acquisitions, explore Business Strategy.